### Diabetes Insipidus Overview
- **Definition**: Passage of large volumes of dilute urine (<300 mOsmol/kg), >3L/day (>2L/day in children).
- **Physiology**: Hypernatraemia stimulates thirst and ADH release; both reduce serum osmolality.

### Types of Diabetes Insipidus
1. **Nephrogenic Diabetes Insipidus (NDI)**: Kidneys fail to respond to ADH.
2. **Central Diabetes Insipidus (CDI)**: Posterior pituitary fails to release ADH.

### Prevalence
- Rare condition: 1 in 25,000.
- NDI less common than CDI.
- Acquired causes notably include chronic lithium therapy (30% incidence).

### Causes of NDI
1. **Common causes**:
   - **Lithium therapy**: Prevents aquaporin 2 channel expression.
   - **Hypercalcaemia**: Disrupts medulla saltiness, affecting water diffusion.
   - **Hypokalaemia**: Milder NDI, pathophysiology not fully understood.

2. **Rare causes**:
   - Sickle cell disease trait
   - Renal amyloidosis
   - Sjögren’s syndrome
   - Post-obstructive uropathy
   - Medications (vasopressin receptor antagonists)

3. **Hereditary NDI**:
   - Caused by mutations in ADH receptor or aquaporin 2 channel (90% X-linked).
   - Early recognition is crucial.

### Symptoms of NDI
- **Polyuria**: Increased urination, often nocturia.
- **Polydipsia**: Intense thirst.
- Symptoms of underlying causes (e.g., lithium toxicity, hypercalcaemia).

### Diagnosis
- **Initial Tests**: Measure Plasma and Urine Osmolality.
  - Expected: High plasma osmolality, low urine osmolality (<300 mOsmol/kg).
  - Urine osmolality >700 mOsmol/kg excludes DI.

- **Water Deprivation Test**: Gold standard for DI diagnosis.
  - Patient refrains from water intake for a period or until specific plasma osmolality levels reached.
  - Desmopressin administered to differentiate DI types.
    - Urine osmolality >700 mOsmol/kg: Excludes DI.
    - Urine osmolality <300 post-desmopressin:
      - >300 = CDI
      - No significant change = NDI.

- **Electrolyte Monitoring**: Check calcium, potassium, and lithium levels for NDI.

### Management (Prescribing)
1. **Correct underlying disorder** or discontinue problematic agents.
2. **Symptom management**:
   - **First-line**: Thiazide diuretics to enhance water/sodium reabsorption.
   - **Second-line**: Amiloride if polyuria persists.
   - **Third-line**: NSAIDs (Indomethacin) to inhibit prostaglandins, supporting ADH action.
   - Consider desmopressin trial if resistant to above treatments.

### Management (Non-prescribing)
- **Hydration**: Maintain adequate fluid intake to prevent complications like hypernatremia.
- **Diet**: Low-salt and low-protein diet to reduce solute excretion and water requirement.
- **Double voiding**: Technique to help young patients ensure adequate bladder voiding and prevent bladder damage.

### References
- UpToDate: [Nephrogenic Diabetes Insipidus](https://www.uptodate.com/contents/search?search=nephrogenic%20diabetes%20insipidus&sp=0&source=USER_INPUT&searchOffset=1&autoComplete=true&language=en&max=10&index=0~6&autoCompleteTerm=nephrogeni)